OUR COMPANY


Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on conjugated antibodies, designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos’ flagship product, T-Guard®, is being prepared to enter Phase 3 testing for the treatment of acute Graft-versus-Host-Disease (aGVHD).

//]]>